Background: Testing for 25-hydroxyvitamin D [25(OH)D] has increased dramatically in recent years. The present report compares overall utilization and results for 25(OH)D orders at two academic medical centers -one in New York and one in Iowa -in order to characterize the vitamin D status of our inpatient and outpatient populations. Results are also compared to those from a national reference laboratory to determine whether patterns at these two institutions reflect those observed nationally. Methods: Retrospective data queries of 25(OH)D orders and results were conducted using the laboratory information systems at Weill Cornell Medical College / New York Presbyterian Hospital (WCMC), University of Iowa Hospitals and Clinics (UIHC), and ARUP Laboratories (ARUP). Chart review was conducted for cases with very high or low serum 25(OH)D levels in the WCMC and UIHC datasets.
Background
Vitamin D is a fat-soluble vitamin important for calcium absorption and bone health. Vitamin D also plays an important role in a variety of other functions, including muscle strength, cellular proliferation, differentiation, and immunomodulation to name a few (see [1] for review), and deficiency may be associated with a variety of clinical conditions and disease states [2] . Vitamin D 2 2 D or vitamin D itself) due to its longer half-life, less day to day variation, and ease of measurement in the clinically relevant concentration range [3] .
Growing interest in vitamin D has led to a dramatic increase in 25(OH)D testing in recent years [4] . This surge in 25(OH)D orders has been a challenge for clinical laboratories deciding whether to handle this testing in-house or as send-outs to commercial reference laboratories. Multiple vendors now offer assays for 25 (OH)D testing, which include immunochemical, chromatographic, and mass spectrometric platforms [5, 6] . Numerous studies, however, have demonstrated variability of 25(OH)D results across assays [7] [8] [9] [10] . Unfortunately, variability between assays can impact studies that examine the prevalence of vitamin D deficiency in populations, as well as clinical decisions for an individual patient [11, 12] .
There is actually little consensus on reference intervals used to determine what are optimal, sufficient, insufficient, deficient, and/or toxic levels of 25(OH)D [13] . For example, the Institute of Medicine (IOM) has recently defined four categories of 25(OH)D status: risk of deficiency (<30 nmol/L; <12 ng/mL), risk of inadequacy (30-49 nmol/L; 12-19 ng/mL), sufficiency (50-125 nmol/L; 20-50 ng/mL); and above recommended levels (>125 nmol/ L; >50 ng/mL) [14] . Data from the National Health and Nutrition Examination Survey (NHANES) was originally analyzed to assess the vitamin D status of the United States population [15] , and has more recently been reviewed with these categories in mind [14] . The Endocrine Society's 2011 clinical practice guidelines, however, describe vitamin D deficiency as 25(OH)D of < 50 nmol/L (<20 ng/mL) and insufficiency as 52.5-72.5 nmol/L (21-29 ng/mL) [16] . Reference intervals may also vary based on assay package inserts, population-specific studies, and/or reference laboratory [13] .
In the present report, we compare the ordering and result patterns of 25(OH)D testing at two large academic medical centers: one in New York City (WCMC) and one in Iowa City (UIHC). We subsequently compare 25 (OH)D results, as well as the distribution of results into reference intervals by age, to those observed at a national reference laboratory (ARUP). Finally, chart review was performed for cases of vitamin D toxicity and deficiency to identify possible patterns in clinical presentation and/or causality.
Methods

General
This report presents data from three separate retrospective reviews of 25 
ARUP study
Using a protocol approved by the University of Utah Institutional Review Board, a de-identified list of immunoassay results for 25(OH)D (DiaSorin immunoassay) was obtained from the ARUP LIS. Exclusion criteria were any specimens potentially received from WCMC or UIHC to prevent duplication of results.
UV index
UV index information is available in the public domain from the Climate Prediction Center, National Weather Service/National Oceanic and Atmospheric Administration website [17] . UV index is defined by the National Weather Service as "forecast of the amount of skin damaging UV radiation expected to reach the earth's surface at the time when the sun is highest in the sky (solar noon)" [18] . The daily "Issued UV Index" is used throughout this paper and incorporates cloud information (as opposed to "clear sky UV index"). Issued UV index was used from the weather station at the John F. Kennedy International Airport (~40.64°N latitude) in New York (near WCMC4 0.77°N latitude) and the weather station at the Des Moines International Airport (~41.53°N latitude) in Iowa (near UIHC~41.66°N latitude).
Limit of quantitation and exclusions
Assays for 25(OH)D have a lower limit of quantitation.
Results below this are typically reported with a "less than" (<) symbol. For the duration of time evaluated in this study, the following were the lower limits of quantitation evident in results of our queries from 2000 through 2012: Nichols Advantage (< 7 ng/mL), ARUP (< 4 ng/mL or < 7 ng/mL), Abbott (< 4 ng/mL or < 7 ng/mL), Roche (< 5 ng/mL). Analysis of ordering patterns and frequency was not impacted by these "less than" results and includes all available data. Area plot analysis (see below) also includes all "less than" results, as they could be fit within the same interval category (ex. 0-10 ng/mL). Cross-tabulation in SPSS 18 (PASW; IBM, Armonk, NY) was used to calculate the proportion of results by age that fall into specific reference intervals. These results were used to generate area plots in SigmaPlot, which display stacked, proportionate areas such that the sum at age is equal to 100% (see corresponding legend for a description). Data throughout the manuscript are presented as mean ± standard deviation (SD) unless otherwise indicated. Since results demonstrated a non-normal 25(0H)D distribution of scores, statistical significance was evaluated using the Mann Whitney rank sum test (with alpha set at 0.05 for the threshold of significance).
Results
25(OH)D by immunoassay
In the 20 months of testing analyzed at WCMC, 57,433 clinician orders for 25(OH)D by immunoassay and 8,439 orders for 25(OH)D by LC-MS/MS were identified. As 25(OH)D results can differ by methodology, WCMC LC-MS/MS orders were not included in initial ordering and result analysis, but are analyzed separately and in the chart review of deficiency cases. In the 153 months analyzed at UIHC, 60,237 orders for 25(OH)D by immunoassay were identified. Total number of immunoassay results reviewed from WCMC, UIHC, and ARUP are included in Table 1 . Table 2 provides summary statistics by platform for 25(OH)D immunoassay testing at UIHC.
The vast majority of tests were ordered on outpatients (versus inpatients) at both WCMC (95.4%) and UIHC (91.2%) ( Table 1 ). The total number of monthly 25(OH)D orders increased dramatically over the interval of time studied at both WCMC ( Figure 1A ) and UIHC ( Figure 1B ). This increase was most prominent between 2008 and 2010 at both institutions (ex. 2008 to 2009 annual growth rates were 115% at WCMC and 52% at UIHC). The majority of tests were ordered on female patients, with similar percentages observed across datasets (WCMC 69.8%, UIHC 67.9%; see Table 1 ). The number of 25(OH)D orders in female and male patients at WCMC ( Figure 1C ) and UIHC ( Figure 1D ) are shown by patient age. At both institutions, the predominance of orders in female (versus male) patients begins at approximately age 20 and continues thereafter. At WCMC, the number of test orders in both female and male patients increased steadily between ages of approximately 20 through 70 years old before decreasing ( Figure 1C ). At UIHC, the increase in test orders was more pronounced between the ages of approximately 40 through 60 years old before decreasing ( Figure 1D ). A greater number of orders for pediatric and adolescent patients were observed at UIHC than WCMC ( Figure 1C ,D), although this may also represent differing patient populations, as New York Presbyterian Hospital's largest children's hospital is not on the WCMC campus (therefore, corresponding specimens/results are not included in the WCMC dataset). Figure 3 . While the SD of results within age groups (by gender) is large with overlapping error bars, statistically significant differences were found between female and male patients at most ages. At WCMC ( Figure 3A) , UIHC ( Figure 3B ), and ARUP ( Figure 3C ), average 25(OH)D results were significantly higher in females than males at most ages (notable exception ARUP 0-9 yr olds, Figure 3C ), although this trend was more pronounced at WCMC and ARUP versus UIHC. Table 1 presents average 25(OH)D results (including all ages) for female and male patients by location. The only locations where average 25(OH)D results were statistically higher in men than women had relatively small population sizes (<200 per group). At WCMC, both outpatient populations (private ambulatory and hospital-owned clinics) showed higher 25(OH)D results than inpatients for both women and men (p < 0.001). Both female and male 25(OH)D levels were significantly lower in patients at the hospital-owned clinics versus private ambulatory clinics (p < 0.001), a factor that may be related to different patient populations served and/or ordering practices at these two categories of clinics. At UIHC, 25(OH)D results were also higher in outpatients than inpatients for both genders (p < 0.001). 25(OH)D results were significantly lower in female ICU inpatients than female non-ICU inpatients (p < 0.001), although this was not true when comparing male results between ICU and non-ICU inpatients (p = 0.648).
As it is known that sunlight (specifically UV-B) exposure promotes peripheral conversion of 7-dehydrocholesterol to previtamin D, we analyzed average 25(OH)D results for males and female patients by order month ( Figure 4A ,B) and compared this to reported regional UV Index data from the National Weather Service (see Methods; Figure 4C ,D) recorded at monitoring locations nearest to the respective medical centers. As expected, 25(OH)D results were higher in summer than winter months in both male and female patients with patterns following the seasonal trends as evident in UV Index periodicity.
To view the distribution of all patient results within specific reference intervals, proportional stacked area plots were generated for WCMC ( Figure 5C,D) , UIHC ( Figure 5E,F) , and ARUP ( Figure 5G ,H) and divided into female patients (left column) and male patients (right column). The reference intervals for ARUP (instead of IOM) were chosen as a starting point for area plot generation, since the majority of specimens in this report were actually tested at ARUP. The < 20 ng/mL interval, however, was subdivided into two separate intervals (0-10 ng/mL and 11-19 ng/mL) to improve our ability to view deficiency in these graphs. Since cases of toxicity were rare, data from the >150 ng/mL "possible toxicity" interval used by ARUP were merged into the >80 ng/mL interval as they were too small to be visible when plotted on the graphs. Even the >80 ng/mL interval is difficult to visualize in Figure 5 (blue shading; not always present at a given age). A color coded legend of the intervals displayed is indicated in Figure 5A and applies to all other area plots ( Figure 5C-H) . A description of area plot generation is also provided in the Methods section and is illustrated in Figure 5B Figure 5G,H) datasets. An increase in optimal 25(OH)D levels (yellow shading) was observed after approximately age 50 in the WCMC, UIHC, and ARUP datasets.
25(OH)D by LC-MS/MS
The WCMC inpatient and outpatient electronic health systems permitted clinicians to electronically order 25 (OH)D by immunoassay and/or 25(OH)D by LC-MS/MS, as described in the Methods section. Given the availability of both assays, in our dataset review we identified 443 cases in which both immunoassay and LC-MS/MS were ordered by clinicians on the same specimen. Analysis of these paired results ( Figure 6A Figure 6H , males). While increased scatter is again noted due to the relatively small number of specimens, the overall pattern is relatively consistent with that observed in 25(OH)D immunoassay results ( Figure 5 ).
Chart review -elevated 25(OH)D
Chart review was performed on all UIHC and WCMC patients who had 25(OH)D levels of 100 ng/mL or greater (see Table 3 ). At UIHC, over the nearly 13 years of results reviewed, only 27 patients (~0.05%) had 25 (OH)D levels greater than 150 ng/mL. An additional 82 patients (~0.14%) had 25(OH)D levels between 100 and 150 ng/mL. The highest 25(OH)D level at UIHC (851 ng/mL) was seen in a patient with X-linked hypophosphatemia. There were only 3 additional patients with a 25(OH)D level of 300 ng/mL or higher. For patients with 25(OH)D of 126 ng/mL or greater in the UIHC dataset, 27.5% were observed in patients taking a 50,000 unit vitamin D 2 prescription more often than once weekly. An additional 31.4% were attributed to patients taking very high doses of over-the-counter vitamin D supplements outside of physician recommendations. Interestingly, only 3 patients out of the 109 total who had 25(OH)D of 100 ng/mL or greater had hypercalcemia (defined as above upper limit of age-specific reference range for total and/or ionized calcium). Only one of these patients was hospitalized for management of hypercalcemia -a 70 year old female with dementia and acute renal failure in addition to hypercalcemia with a 25(OH)D level of 194 ng/mL. There were no cases of vitamin D-based rodenticide poisoning in the UIHC dataset.
In the UIHC review there were only 3 pediatric patients (17 years or younger) who had 25(OH)D of 126 ng/mL or Figure legend showing the colors representing reference intervals used in B through H. An asterisk (*) is indicated next to the >80 ng/mL intervals (blue) in A and B, as this interval often contains too few specimens to be easily visible at this magnification (also evident in C through H). B. Presentation of population data as area plots. For any given group (for example, WCMC female patients age 45 shown here) the percent of patients that fall into specific reference intervals can be represented as a pie chart (B, left example). To the right of the pie chart is a "proportional stacked plot" (B, middle) that shows the same data, but now stacked by color-coded reference intervals (low to high) such that the sum of all areas equals 100%. These data can also be presented as a narrower stacked color-coded "single line" (B, right). Graphing "single line" area plots for all ages (aligned by increasing age) produce the area plots shown below. C-H. Area plots show the reference interval distributions for all ages (0-100 yrs; 1 yr bins) in females (C, E, G) and males (D, F, H) at WCMC (C,D), UIHC (E,F) and ARUP (G,H). The UIHC dataset does not include any males greater than 97 years old (F). Overlying reference lines (dotted) have been added at 20% intervals to all area plots (C-H) to facilitate comparison across graphs.
greater. The pediatric patients were 23 months old (182 ng/mL), 4 years old (292 ng/mL) and 17 years old (146 ng/mL). The elevated 25(OH)D in the first two patients were attributed to high prescription vitamin D doses which were adjusted once the elevated 25(OH)D serum concentration was known.
At WCMC, over the 20 months of results reviewed, only 15 patients (~0.03%) had 25(OH)D levels > 150 ng/mL, with an additional 35 (~0.06%) having a measurement between 100 and 150 ng/mL. Vitamin D supplementation was specifically mentioned in 29 of these 50 cases, with actual and/or estimated doses documented in 24 of these In 12 of the 50 WCMC patients identified with 25(OH)D levels of 100 ng/mL or greater, bone disease (osteoporosis, osteopenia, scoliosis, and/or fracture) was documented by the clinicians. Four of the 50 WCMC cases showed vitamin D supplementation in the context of Crohn's disease, ulcerative colitis, and/or inflammatory bowel disease. Five of the 50 WCMC cases showed vitamin D supplementation in the context of multiple sclerosis.
Chart review -decreased 25(OH)D
Chart review was also conducted to investigate possible causes for severe 25(OH)D deficiency in UIHC and WCMC patients (Table 4) . For the UIHC dataset, chart review was conducted for cases of "severe vitamin D deficiency" with total 25(OH)D < 5 ng/mL. This occurred in 185 patients over a 13 year period. A likely primary cause of severe vitamin D deficiency could be ascertained from chart review in 134 out of 185 patients (72.4%). The most common suspected causes were severe dysfunction of the liver and/or biliary tract (n = 26), lipid malabsorption syndrome (n = 25, examples included cystic fibrosis, abetalipoproteinemia, celiac disease, and inflammatory bowel disease), and morbid obesity/post-gastric bypass surgery (n = 23). Only 54 of 185 (29.2%) patients had a total calcium serum concentration below age-appropriate reference range at time of 25(OH)D measurement. Forty patients were not taking vitamin D supplements prior to 25(OH)D measurements.
For the WCMC dataset, chart review was conducted for cases of "severe deficiency" where 25(OH)D 2 and 25 (OH)D 3 results by LC-MS/MS were both <4 ng/mL. Of 8,439 orders for 25(OH)D by LC-MS/MS, 14 distinct patients (0.17%) met this criteria. One of these 14 patients, however, had a separate 25(OH)D result by immunoassay reported on the same specimen with discordant results of 21 ng/mL. As no clinical history was available for this patient, it was excluded from further analysis due to possible mix-up and/or analytical error. Of the remaining 13 patients (see Table 4 ), three had a history of prior bariatric surgery (one with complications), one presented for a pre-operative evaluation for bariatric surgery, three had renal failure (two were status post renal transplant while the other had nephrotic syndrome), one [22] , as was frequent milk consumption and white racial background among other factors [23] . It should be noted that American female adolescents report consuming less milk than male adolescents [24] , and in general, girls (during childhood and adolescence) have been reported to spend less time outdoors than boys [21] . These factors may contribute to the patterns observed for female adolescents throughout this report.
We suspect that increased use of vitamin D-containing supplements (specifically vitamin D 3 ) during later adulthood contributes to the improved 25(OH)D status observed at those ages [25] . Elevation of 25(OH)D 3 levels as measured by LC-MS/MS ( Figure 6C,D) supports this hypothesis. Increased use of supplemental vitamin D in women versus men is also likely to contribute to the more optimal 25(OH)D status in women seen in our report [25] .
It should be noted that another large study of approximately 158,000 individuals who had 25(OH)D testing performed at Calgary Laboratory Services in Alberta, Canada also found higher 25(OH)D levels in female than male patients and improved mean 25(OH)D levels later in adulthood (described as a nadir in early adulthood) [26] . A population-based study in São Paulo, Brazil of 636 participants showed similar correlations regarding age, sex, and mean 25(OH)D concentrations [27] . Other population studies, however, have shown higher 25(OH) D values in males than females [28] . Finally, seasonal/ UV-B dependent variation in 25(OH)D levels have been well-characterized in numerous prior studies [29] [30] [31] [32] [33] [34] [35] , as well as a more recent excellent report analyzing 3.44 million U.S. patient samples [36] .
It is tempting to speculate that differences in 25(OH)D levels between females and males could also be due to differences in circulating vitamin D binding protein (DBP; also known as Gc globulin). For example, some previous studies have found higher circulating DBP levels in women versus men [37, 38] , including higher levels in pregnant [9] . One limitation of the present study is that patient ethnicity was not available in our datasets; therefore, results could not be subdivided by race. It is reasonable to assume that WCMC and UIHC 25(OH)D datasets may not be fully representative of national demographic patterns. U.S. Census data for 2010 reports an 86.1% white ethnicity in zip code 10065 (WCMC) and 88.8% white ethnicity in zip code 52242 (UIHC) [43] . These percentages, however, are likely much higher than the percent of white populations observed at these facilities, which both provide inpatient and outpatient care to patients far beyond a single zip code. No demographic information was available for the ARUP dataset, but it may be more representative of the U.S. population as a whole due to its status as a national reference laboratory. Finally, we were not able to control for any potential gender differences in the relative likelihood of visiting a healthcare provider in our patient populations.
Other limitations of the present report are the variability inherent to including multiple immunoassay platforms in our datasets (see Methods), as well as any potential shortand/or long-term changes in assay performance characteristics that can sometimes be observed in the clinical laboratory setting. While we observed differences in average 25(OH)D results across different assay platforms (see Table 2 ), it is important to note that ordering practices for 25(OH)D testing have dramatically shifted over time. A change from prior testing primarily for clinically suspected deficiency toward the more recent widespread utilization of such testing in otherwise healthy individuals likely confounds the attempt to utilize our dataset for direct assay comparisons. As our all of the testing, however, was ordered by clinicians and used in the management of patient care, we believe that it is appropriate to include all available data for patient averages and reference interval distributions in the present report, while acknowledging that some degree of bias may be introduced by including multiple assays in such analysis.
In our chart review, most cases of 25(OH)D levels greater than 150 ng/mL (potentially toxic) were due to vitamin D over-supplementation (especially use of 50,000 IU prescription vitamin D 2 at weekly or greater intervals, intake of prescribed daily vitamin D that approximated or exceed weekly totals of >50,000 IU, and/or very heavy use of over-the-counter supplements outside of physician recommendations). Frequently, however, vitamin D intake was not well documented. In some cases, the dose recorded in the patient's chart was far below what would be expected to cause potentially toxic levels. It is unclear whether this represented inaccurate/incomplete documentation or hypersensitivity to vitamin D.
It should be noted that elevated 25(OH)D results were uncommon at both UIHC and WCMC. For the UIHC population, only 27 of 60,237 tests (~0.05%) ordered over an approximately 13 year period had values >150 ng/mL. Of these 27 patients, only three had hypercalcemia and only one was hospitalized in critical condition. At WCMC, 15 of 57,433 orders for 25(OH)D by immunoassay (~0.03%) had values > 150 ng/mL. Of these 15, only four had hypercalcemia and only one was hospitalized (also in critical condition). While it was clear that documentation of over-the-counter supplementation was frequently absent or incomplete in our chart review, it is possible that vitamin D toxicity may only been suspected when symptoms (and/or laboratory findings) consistent with hypercalcemia were observed. In this era of increased attention to (and supplementation of) vitamin D, it would be prudent to keep the possibility of vitamin D toxicity in the differential diagnoses of patients receiving large doses of vitamin D 2 or vitamin D 3 .
Conclusions
In conclusion, the present report describes the order and result patterns for 25(OH)D testing at two large academic medical centers, and shows that these data are reflective of results observed at a national reference laboratory. Future studies on large populations may be necessary to fully understand vitamin D status throughout life.
